OBJECTIVE: Maintenance chemotherapy is a recently approved approach to the treatment of advanced non-small cell lung cancer (NSCLC). We sought to gain insight into patients' perceptions of maintenance chemotherapy using qualitative methods. METHODS: We conducted thematic content analysis of focus groups at a freestanding cancer center and at an associated safety-net county hospital. Patients with advanced NSCLC who had started but not yet completed first-line platinum doublet chemotherapy were provided visual and written explanations of maintenance chemotherapy before being guided in group discussion. RESULTS: Key themes to emerge for consideration of maintenance chemotherapy included: (1) survival benefits, disease control, and "buying time"; (2) the importance of "doing something"; (3) quality of life concerns; (4) the role of provider opinion/preference; and (5) the importance of logistics. CONCLUSIONS: Patients undergoing first-line chemotherapy for advanced NSCLC were able to understand the concept of maintenance chemotherapy, distinguish it from traditional treatment paradigms, identify pros and cons of this approach, and convey reasons for considering it. PRACTICE IMPLICATIONS: Advances in oncology care that alter therapy modalities and delivery may significantly impact patient perceptions and treatment experiences. Clinical team members may wish to elicit treatment preferences of first-line patients through clinical discussion that anticipate these considerations.
OBJECTIVE: Maintenance chemotherapy is a recently approved approach to the treatment of advanced non-small cell lung cancer (NSCLC). We sought to gain insight into patients' perceptions of maintenance chemotherapy using qualitative methods. METHODS: We conducted thematic content analysis of focus groups at a freestanding cancer center and at an associated safety-net county hospital. Patients with advanced NSCLC who had started but not yet completed first-line platinum doublet chemotherapy were provided visual and written explanations of maintenance chemotherapy before being guided in group discussion. RESULTS: Key themes to emerge for consideration of maintenance chemotherapy included: (1) survival benefits, disease control, and "buying time"; (2) the importance of "doing something"; (3) quality of life concerns; (4) the role of provider opinion/preference; and (5) the importance of logistics. CONCLUSIONS:Patients undergoing first-line chemotherapy for advanced NSCLC were able to understand the concept of maintenance chemotherapy, distinguish it from traditional treatment paradigms, identify pros and cons of this approach, and convey reasons for considering it. PRACTICE IMPLICATIONS: Advances in oncology care that alter therapy modalities and delivery may significantly impact patient perceptions and treatment experiences. Clinical team members may wish to elicit treatment preferences of first-line patients through clinical discussion that anticipate these considerations.
Authors: Judith E Nelson; Elizabeth B Gay; Andrew R Berman; Charles A Powell; John Salazar-Schicchi; Juan P Wisnivesky Journal: Cancer Date: 2011-04-14 Impact factor: 6.860
Authors: Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee Journal: Cancer Date: 2006-05-01 Impact factor: 6.860
Authors: Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly Journal: Lancet Date: 2010-12-20 Impact factor: 79.321
Authors: Heidi A Hamann; Jamie S Ostroff; Emily G Marks; David E Gerber; Joan H Schiller; Simon J Craddock Lee Journal: Psychooncology Date: 2013-10-03 Impact factor: 3.894
Authors: David E Gerber; Muhammad Shaalan Beg; Tobi Duncan; Mary Gill; Simon J Craddock Lee Journal: Oncol Nurs Forum Date: 2017-03-01 Impact factor: 2.172
Authors: Monika Sztankay; Johannes Maria Giesinger; August Zabernigg; Elisabeth Krempler; Georg Pall; Wolfgang Hilbe; Otto Burghuber; Maximilian Hochmair; Gerhard Rumpold; Stephan Doering; Bernhard Holzner Journal: BMC Cancer Date: 2017-08-23 Impact factor: 4.430
Authors: L M Wintner; J M Giesinger; A Zabernigg; M Sztankay; V Meraner; G Pall; W Hilbe; B Holzner Journal: Br J Cancer Date: 2013-10-03 Impact factor: 7.640